EULAR cited in fibromyalgia fasting piece

Fibromyalgia treatment is one of those areas where patients keep hearing about promising add-ons, but the core playbook barely changes. That is basically what happened here. A Rheumatology Live piece pulled attention to a 2024 study on prolonged medical fasting in fibromyalgia, then anchored it back to EULAR’s existing management recommendations. So the real development is not a new guideline — it is a reminder that any fasting idea still sits outside the main evidence-backed framework. ### What was the actual study? The paper came from Immanuel Hospital Berlin and looked at 176 patients with fibromyalgia syndrome treated between February 2018 and December 2020 in an inpatient, multimodal program. It was not a randomized head-to-head trial. It was a single-arm observational study, which means everyone got the intervention and there was no separate control group to prove fasting caused the improvement by itself. (rheum-live.com) ### What did “fasting” mean here? This was not casual intermittent fasting at home. Patients underwent medically supervised prolonged fasting for 3 to 12 days, taking in less than 600 kcal per day, inside a broader inpatient treatment program. That broader setup matters a lot, because the fasting was bundled with multimodal care rather than tested as a standalone trick. (pmc.ncbi.nlm.nih.gov) ### Did patients actually improve? Yes — on paper, several measures moved in the right direction. The Fibromyalgia Impact Questionnaire total score fell by 13.7 points at discharge. Pain on a numeric rating scale dropped by 1.1 points. Quality-of-life scores improved, and the paper says some of those gains appeared to persist through follow-up visits. Anxiety and depression scores also improved during inpatient treatment, though those effects did not look as durable later on. (pmc.ncbi.nlm.nih.gov) No serious adverse events were reported during the study period. ### So why isn’t this a guideline-changing moment? Because the design leaves a big unanswered question — what exactly did the work? If patients are fasting, resting, getting structured inpatient care, and receiving other non-drug therapies at the same time, you cannot cleanly isolate the fasting effect. It is a bit like changing the tires, engine tune, and fuel all at once, then trying to say which single fix made the car faster. The results are interesting, but they are not the kind of evidence that usually rewrites standard care. (pmc.ncbi.nlm.nih.gov) ### Where does EULAR fit in? EULAR’s fibromyalgia recommendations are still the main rheumatology framework here, and they are older than this fasting study. The 2017 revised recommendations emphasize a graduated approach, shared decision-making, patient education, and a first-line focus on non-pharmacological treatment. Exercise stands out as the only therapy with a “strong for” recommendation in the guideline set. (pmc.ncbi.nlm.nih.gov) ### Does EULAR recommend fasting? Not in the guideline framework surfaced here. The patient summary emphasizes non-drug care first and specifically highlights aerobic and strengthening exercise, with CBT also listed among supported options. Fasting is better understood as an experimental or adjunctive idea that might fit inside broader lifestyle-oriented care, not as an endorsed standard treatment on the same footing as exercise. (ard.bmj.com) ### Why does that distinction matter? Because fibromyalgia is full of treatments that sound plausible, feel helpful for some people, and still do not clear the bar for routine recommendation. Clinicians need something sturdier than “promising” before telling patients to pursue a restrictive intervention — especially one that is intensive enough to require supervision. The Rheumatology Live framing is useful because it keeps that hierarchy intact. (eular.org) ### What should readers take from this? The fasting study is real, and the signal is worth watching. But the center of gravity has not moved. Fibromyalgia care in rheumatology still starts with education, exercise, and other non-drug strategies, while fasting remains an intriguing side road that needs stronger trials before it can join the main map. (pmc.ncbi.nlm.nih.gov) (rheum-live.com)